•
Mar 31, 2023

OptimizeRx Q1 2023 Earnings Report

Reported first quarter 2023 financial results.

Key Takeaways

OptimizeRx reported a solid start to 2023 with total revenue of $13.0 million. The company's execution remains on pace to meet its 2023 financial and operational objectives.

Total revenue was $13.0 million.

GAAP net loss per share was $(0.37).

Non-GAAP net loss per share was $(0.09).

Reaffirmed full year financial outlook for net revenue to increase at least 10% year-over-year.

Total Revenue
$13M
Previous year: $13.7M
-5.3%
EPS
-$0.09
Previous year: -$0.01
+800.0%
Gross Profit
$7.43M
Previous year: $8.08M
-8.0%
Cash and Equivalents
$16.4M
Previous year: $89M
-81.5%
Free Cash Flow
-$115K
Previous year: $4.07M
-102.8%
Total Assets
$132M
Previous year: $138M
-4.7%

OptimizeRx

OptimizeRx

Forward Guidance

The Company is reaffirming its full year financial outlook for fiscal 2023 for net revenue to increase at least 10% year-over-year, and gross margins to be between 58% and 62%.